

- comparative genomic hybridization, 224, 226
computation: in decision-making, 109, 111, 114, 118, 123; in microcircuits, 59, 60, 61; in vision, 126, 128, 138
concepts: in abstract reasoning, 167, 179; in perception, 139, 143, 145
conduct disorder, 83, 216
cone cells, 126, 127, 128, 137
confidence: in decision-making, 110, 115; in risk management, 96; self-help and, 267, 269
congenital adrenal hyperplasia, 194, 202, 205
connectivity: in agnosias, 143; cell type specificity of, 57; and emergent functions, 249; functional, 25; sex differences in, 196–97, 199; structural, 23, 75, 80; synaptic, 199, 237; in synesthesia, 152
conscientiousness, 1, 50, 101–102; and educational attainment, 173; effects of maltreatment on, 83; heritability of, 20; reinforcement of, 96; and self-help, 268; sex differences in, 206
consciousness, 157
control, effortful, 102, 208
cooking, 156
copy number variants. *See* CNVs
corpus callosum, 71, 72, 73, 192; sex differences in, 198
correlation coefficient, 16, 17, 19
cortex: anterior inferior temporal, 149; cell migration in, 70, 148; cerebral, 60, 61, 64–65, 70–71, 72, 192; evolution of, 157; and intelligence, 175; neuromodulatory inputs to, 93, 113, 114; orbitofrontal, 116; plasticity in, 93; prefrontal, 99, 113, 116, 242; sex differences in, 195; visual, 87, 89, 127, 128–30, 138, 143, 149
crime, 204, 214
CRISPR/Cas9, 247, 256
critical periods: in sensory systems, 90; in sexual differentiation, 190, 194, 204
culture, 3, 53, 98, 157, 170; effects on sex differences, 183, 204–205, 207, 209, 213–14
Curie, Marie, 180
cystic fibrosis, 232
cytosine, 33
Darwin, Charles, 180, 186
Darwin, Erasmus, 180
Davenport, Charles, 254, 256, 262
de novo mutation, 37–42, 43; and intelligence, 163, 181; and neurodevelopmental disorders, 224, 227, 229–30, 233, 245–46
deafness, 133–34, 220, 241, 253
decision-making: and human personality, 110–124; and impulsivity, 115, 115–116, 118, 122–124; parameters, 110, 110–114; in robots, 107–109
deep brain stimulation, 247
del Giudice, Marco, 206
delay discounting, 110, 115
deletion syndrome, 22q11, 223, 225, 226
deletions. *See* chromosomes, deletions or duplications of segments of
delusions, 49
dementia, 213
dendrites, 21, 57, 58, 59, 62; and synaptic plasticity, 87, 111
deoxyribonucleic acid. *See* DNA
determinism, 264–65
developmental brain dysfunction, 233, 239
developmental delay, 225, 228, 237, 239
developmental program, 64–65, 77–79, 86, 90, 257; robustness of, 178–79
developmental variation, 54, 70, 73–75, 78, 81, 86, 97, 195, 248; and intelligence or IQ, 179; and neurodevelopmental disorders, 233; and perception, 143; and personality traits, 124; and sexual differentiation, 201, 211
dichromatic (vision), 136, 136–37
differentiation, cellular, 36, 55–56, 69, 135, 268
differentiation, sexual. *See* sexual differentiation
diffusion-weighted imaging, 23. *See also* imaging or neuroimaging
dimorphism, sexual, 186, 191, 192, 196, 208
direct-to-consumer genetic profiling, 258
disability, intellectual, 120, 142, 162, 162–63, 170–72, 181, 210–12, 217, 219, 223, 225, 226, 227–28, 233, 237–39, 241, 252, 256
distribution, normal, 18, 19, 48
diversity, genetic, 184, 259–61
DNA, as genetic material: 31–33, 34, 35
DNA replication, 33, 38, 39, 40, 225, 227
DNA sequence, 4, 9; evolutionary constraint, 176; information in, 32–33, 34, 35–37; repeats, 172, 225; variation in, 37–38, 39, 40, 44–45, 55, 104, 105, 173, 227–28
DNA sequencing, 228, 253
dogs: selective breeding of, 6, 6–7, 254, 259; sensory abilities of, 132–34
domestication, 5

- dominance: displays, 186; in dogs, 6; in mice, 98; personality trait, 100; sex differences in, 206–207, 209
- dopamine: in decision-making, 111–12, 113, 116–17; and personality traits, 104, 109; in schizophrenia, 242, 244. *See also* neuromodulators
- double helix, 33
- Down syndrome, 27, 40, 162–63, 246, 253
- Dravet syndrome, 246
- drift, genetic, 44, 171, 258
- drug abuse, 20. *See also* substance abuse
- dualism, 265
- duplications. *See* chromosomes, deletions or duplications of segments of
- dwarfism, 48–49, 164–64, 241–42, 253
- dyslexia, 142–43, 212; sex differences in, 235
- education: and intelligence or IQ, 97, 156, 159, 161, 164, 166–68, 263; and sex differences, 212
- educational attainment, 14, 20, 173–74, 235
- EEG, 91, 138, 142, 151, 176
- egg: fertilized, 3–4, 13, 36, 54–55; mutations arising in, 5, 27, 39, 40, 45, 163, 171–72, 181, 184, 188; use in *in vitro* fertilization, 253–54, 258
- Einstein, Albert, 180–81
- electroencephalogram. *See* EEG
- electroencephalography, 176. *See also* EEG
- Ellington, Duke, 146
- embryo, 8, 13, 36; development of, 54–56, 61–62, 69, 79; genome editing in, 247, 256; inherited mutations in, 39, 40; preimplantation screening of, 14, 245, 253–57; sexual differentiation of, 188; somatic mutations in, 230;
- emergent properties, 46, 50, 244, 249, 265
- emergent psychological symptoms, 242, 243, 244, 246
- emotion: in decision-making, 111, 117; in synesthesia, 144, 153
- emotional processing, 83
- emotional responsiveness, 94
- emotional stability, 100; sex differences in, 206–208
- emotional states, 92
- emotional withdrawal, 218
- emotionality, negative, 102
- empathizing, 14, 207
- environment, family or shared, 12–13, 17–19, 28–30, 51–52, 54, 74; and early experience, 83–85; heritability of, 96; and intelligence, 97, 164–166, 168, 180; and neurodevelopmental disorders, 222; and personality traits, 103
- environment, nonshared, 30, 51–52, 54, 74, 85
- environmental effects or factors, 1, 4, 51–54, 73, 77, 86, 122; and intelligence, 161, 164–167, 179, 260, 262; and neurodevelopmental disorders, 218–220, 231, 244; and sexual dimorphism, 208
- environmental variance or variation, 9, 26–28, 52, 66, 167, 244; between groups, 260, 262
- enzymes, metabolic, 35, 57, 238, 246
- epigenesis, 76
- epigenetic landscape, 74, 76–77
- epigenetics, 76, 81, 268–69
- epilepsy, 10, 59, 148, 172, 218, 221, 223, 225, 226, 228, 233, 234, 238, 241, 246; and eugenics, 252, 254; probabilistic effects on inheritance of, 70, 75, 148
- estrogen, 189–91, 193–94
- estrous cycle, 189, 192, 213
- ethics, 254
- eugenics, 14, 158, 252–258
- evolution, 48, 64, 76–77, 90; cultural, 157–58; human, 3, 262; of intelligence, 156–58, 170, 177–78; and neurodevelopmental disorders, 224, 239–40; and sex, 185–87, 199, 204, 207–209, 258
- executive function, 116
- experience: early, 82–86; subjective, 11, 91, 92, 94, 111, 134, 138, 145, 265
- extraversion, 7, 14, 20, 46, 49, 100–102; genetics of, 104–105; GWAS of, 106; and impulsivity, 114, 115; sex differences in, 206
- eye color, 47, 169, 249
- Eysenck, Hans, 100–101
- face blindness, 139–140, 141, 141–42, 154, 253
- face-processing network, 141
- faces: sex differences in, 187, 196, 197, 204, 206, 211; symmetry of, 66, 66, 78–79, 178, 211; variation in, 5, 8, 50, 65–66, 66, 258; visual processing of, 127, 129, 140–42
- failure modes, 244
- family environment. *See* environment, family or shared

- Farina, Francesca, 152
fear, 117
fearfulness, 5
feedback: in experience-dependent development, 90, 94, 96–97, 99, 205, 244; in evolution of intelligence, 158; genetic, 56, 69, 76–77; in visual system, 130
feminization, 189, 190, 196, 201, 203
fertilization, 40, 75, 184; in vitro, 245, 253
fetal biochemistry and physiology, 77
fetal brain, 8, 174; genes expressed in, 236
fetuses, 79, 185, 190; prenatal screening of, 253
Feynman, Richard, 180
fingerprint, neural, 25
fitness, evolutionary, 41–42, 44–45, 79, 250, 260; and intelligence, 176–78, 235, 256, 263; and sexual selection, 186–87
flexibility: cognitive, 118, 155, 157; in neural development, 90–91, 99
flicker detection, 132, 138
Flynn effect, 166
Flynn, James, 166
fMRI. *See* magnetic resonance imaging, functional
foraging, 186
forebrain, 8, 57, 114
four humors, 112
foxes, 7
fragile X syndrome, 162, 223, 226, 234, 246
fragility of complex systems, 77
free will, 265–66
Freud. *See* psychology, Freudian
frontal lobes, 70; and intelligence, 175; in perception, 140, 141, 142–43. *See also* cortex: prefrontal; orbitofrontal
functional magnetic resonance imaging. *See* magnetic resonance imaging, functional
fusiform face area, 140
fusiform gyrus, 140

g. *See* intelligence, general
Galen, 112
Galton, Francis: and behavioral traits, 14; and correlation, 17; and eugenics, 14, 254, 256, 262; and intelligence, 180; and synesthesia, 145, 149
gametes, 39
Gattaca, 79, 258
Gauss, Carl, 180
gender: identity, 194, 202; roles, 205, 207
gene(s): definitions of, 31, 37–38; regulatory regions of, 36–37; relationship to traits, 249–50, 251, 252; structure of, 32–33, 34, 35–37
gene by environment interaction, 121–22
gene expression, 35–37, 55–56, 76; and epigenetics, 76, 84, 268; noise in, 68–69; and serotonin, 120; in sex determination, 188; sex differences in 192–93, 196, 199, 213
genetic architecture, 10; of behavioral or psychological traits, 250, 251, 259–60; of intelligence, 169–70, 256; of neurodevelopmental or neuropsychiatric disorders, 222, 223; of personality traits, 123; of sexual orientation, 202
genetic code, 33, 34, 35
genetic information, 2, 4, 14, 32–33, 35–36, 40, 67, 90, 245, 252–55, 257–58
Genetic Information Nondiscrimination Act, 257
genetic prediction, 252–58
genetic program, 4–6, 23, 86, 251; and intelligence, 158, 176; robustness of, 236, 240; and sexual differentiation, 193, 201
genetic variation, 5–10; dynamics of, 41–45; effects of, 45–50; and epigenetic landscape, 76; and group differences, 262; and heritability, 12, 20, 30; and intelligence or IQ, 159, 169; and neurodevelopmental disorders, 230; and perception, 125, 133, 137; and personality traits, 103, 114, 121, 123–24; relation to psychological traits, 248–50, 251, 252; and sex differences, 195
genetics, quantitative, 169–70
genius, 153, 179–82, 240
genome, human. *See* human genome
genome editing, 247, 256
genome sequencing, 226, 228, 245; fetal, 253
genome-wide association study. *See* association study, genome-wide
germ cells, 184, 188
Germany, 14, 254
germline, 184, 229–30, 256
gibbons, 186
GINA. *See* Genetic Information Nondiscrimination Act
goals, 82, 109, 267
gonads, 188, 189, 192
gorillas, 186
grapheme, 149
gray matter, 21, 23, 152

- gregariousness, 3, 206
grooming, 186
group differences, 195, 258–64
growth cone, 62
guanine, 33
GWAS. *See* association study, genome-wide
- habits or habitual behavior, 91–94, 94, 99, 112, 264, 266; and self-help, 268
hair, red, 47, 49
hallucinations, 49
hallucinogens, 152
handedness, 49, 73–75, 203
harm aversion, 115, 117
Hawke, Ethan, 79
health, and intelligence, 161, 166–66, 177, 178, 256–57, 263
height, 5, 13, 15–16, 18, 19, 26–27, 47–48, 98, 163, 169, 177, 178, 195, 208, 258
hemispheres, cerebral, 21, 64, 71, 72, 178, 197–98
hemoglobin, 35–38, 41, 49
heredity, 27, 31, 33, 37, 48, 249, 254
heritability, 20, 25–28; of asymmetry, 78; of brain structure, 21, 23; of dyslexia, 143; of epilepsy, 70; of functional connectivity measures, 25; and genetic determinism, 264; of handedness, 74; of impulsivity, 115; of intelligence or IQ, 97, 165–68, 179, 262; of life events, 96; of neurodevelopmental disorders, 221; of sexual orientation, 201
Herrnstein, Richard, 262
heterosexuality, 201–203
high altitude, adaptation to, 259
hindbrain, 8, 57
hippocampus, 61, 191, 242, 244
Hippocrates, 112, 220
Hirschsprung's disease, 234–35
histogram, 18
homicide, 171, 204
hominids, 156, 183, 186
Homo sapiens, 156, 263
homosexuality, 201–203
horizontal cells, 126, 127
hormones: regulating appetite, 49; sex, 188–94, 200, 202, 204, 236; stress, 193
Htr1a, 120. *See also* serotonin receptors
Htr1b, 119. *See also* serotonin receptors
HTR2B, 121. *See also* serotonin receptors
human genome, 2, 6, 26, 35, 37, 41, 44, 54–55, 207, 225, 228
Human Genome Project, 228
human nature, 1–5, 102
hunting, 156, 186
Huntington's disease, 232
hyperconnectivity, 143
hypothalamus, 93, 191, 192, 195
- ibn 'Imran, Ishaq, 221
idiopathic cases of disorders, 222–23, 226
illusions, optical, 130, 131, 138
imaging or neuroimaging, 20–21, 22, 23–25, 70; of brain asymmetry, 178; of brain malformations, 64; and face perception, 140; and intelligence or IQ, 175–76; and perception, 129; and personality, 107, 116; and sex differences, 194–200, 206, 213; and synesthesia, 151;
impulsivity, 20, 114, 115, 115–121
in vitro fertilization. *See* fertilization, in vitro
INAH-3, 191, 192, 195, 202
infection, maternal, 77
inference, active or predictive, 126–29, 130, 131
inheritance, 27, 31, 38; blended, 47–48, 169; discrete or Mendelian, 47–48, 147; of intelligence, 169, 180; of neurodevelopmental disorders, 223; probabilistic, 75; of synesthesia, 147; X-linked, 163
inhibition, behavioral, 117, 119
inhibition, neural, 246. *See also* neurons, inhibitory
instincts, 2, 92, 99, 157
insulin, 35, 36
insurance, 257–58
intellectual disability, 120, 142, 162, 162–62, 170–72, 181, 226; and copy number variants (CNVs), 225, 226, 227; diagnosis, 219, 238–39; and eugenics, 252, 256; in fragile X syndrome, 223; and life expectancy, 217; in metabolic disorders, 238; persistence of, 241; rare mutations in, 228; sex differences in, 210–12
intelligence or IQ: amplification of initial differences in, 97; brain correlates of, 175–76; childhood, 82, 97; and CNVs, 172–73; and cognitive reserve, 177, 178–79; and developmental robustness, 177, 177–79, 235; distribution, 18, 161, 162; and education, 159, 161, 167–68; environmental effects on, 165–69, 263; essence of, 156–58; and Flynn effect, 166–67; general (g), 160; as general fitness indicator, 176–177, 177, 178, 235,

- 256, 263; genetic architecture of, 169–72, 177; genetic prediction of, 258; group differences in, 27, 262–63; GWAS of, 173–74; and health, 161, 177; heritability of, 97, 165–66; and life outcomes, 161; and longevity, 161; measuring, 159–61; and neurodevelopmental disorders, 177, 178–79, 235; and neurodevelopmental genes, 174–75; parenting effects on, 29; and rare mutations, 173; sex differences in, 209, 210, 211–12; and symmetry, 177, 178; twin and adoption studies of, 164–65. *See also* IQ tests
- intelligence quotient. *See* intelligence or IQ
- interests, 20, 28; in autism, 153, 241; sex differences in, 98, 187, 205, 207, 212, 214
- intermittent explosive disorder, 121
- interstitial nucleus of the anterior hypothalamus-3. *See* INAH-3
- inverse problem, 126
- ion channels, 35, 57, 59, 175, 237, 246
- IQ tests, 52, 97, 156, 159, 160, 161; and CNVs, 172; distribution of scores, 161, 162; and education, 167–68; and genius, 179–80; group differences in, 262–63; sex differences in, 209, 210, 211–12; test-retest reliability, 15, 52, 165; twin studies of, 164–66. *See also* intelligence or IQ
- IVF. *See* fertilization, in vitro
- Jackson, Andrew, 132
- Joel, Billy, 146
- Joel, Daphna, 196
- Kandinsky, Wassily, 146
- Kinsey, Alfred, 200
- knowledge, conceptual, 131, 139, 141, 142, 143; and education, 168; in intelligence testing, 159–60;
- lactase, 259
- language, 3, 20, 50, 157, 170; learning, 90–91; in neurodevelopmental disorders, 216, 242, 244
- Law, Jude, 79
- learning, 3, 82, 87, 92, 93, 117, 148; disabilities, 235; and habit formation, 112; and intelligence, 156, 167, 170; and neuro-modulators, 11;
- Leibniz, Gottfried, 180
- lemurs, 156
- leptin, 49
- LeVay, Simon, 202
- Lewis, Marc, 99
- Lindbergh, Charles, 254
- Liszt, Franz, 146
- lithium, 217
- longevity, 161, 256
- LSD. *See* lysergic acid diethylamide
- lysergic acid diethylamide, 152
- macrocephaly, 237
- magnetic resonance imaging (MRI), 20–21, 22, 23, 107; functional (fMRI), 24. *See also* imaging or neuroimaging
- maltreatment, childhood, 82–85, 122
- mania, 266
- MAOA. *See* monoamine oxidase A
- masculinization, 189, 190–91, 193–94, 196, 201–203
- mating, 108–109, 184–86, 204, 260
- Matrix, The, 133
- maturation, 2–3, 7, 23, 73, 82, 86, 99, 168, 198, 243, 267; sexual, 200, 208
- mechanosensation, 135
- melanocortin 1 receptor, 49
- memory, 14, 20, 87, 170; in neurodevelopmental disorders, 242; in perception, 139, 141, 143; in savants, 153, 181; working 159
- Mendel, Gregor, 31, 37, 47–48
- Mendelian inheritance, 47–48, 140, 147, 232
- mental illness. *See* psychiatric disorders
- mescaline, 152
- messenger RNA, 34, 35–37, 68
- Messiaen, Olivier, 146
- microarray, 224, 227
- microcircuit, 3, 59, 89, 249
- midbrain, 8, 57, 112, 113, 117, 242
- migraine, 213
- migration, cellular, 61–62, 64, 69–70, 123, 148, 174, 237, 242
- mindfulness, 266
- monkeys: brain size in, 156; color vision in, 136; decision-making in, 115; sex differences in, 190, 204
- monoamine oxidase A (MAOA), 119, 120–22
- monogamy, 3, 185
- mood, 111–12, 216–17, 242, 267; disorder, 83
- morphology, facial, 5, 196, 197, 206, 223, 258
- mortality: infant, 171; and intelligence, 171, 178; in psychiatric disorders, 217

- mosaic: male-female brain, 196; of somatic mutations, 230
- mothers, refrigerator, 218
- MRI. *See* magnetic resonance imaging (MRI)
- mRNA. *See* messenger RNA
- multiple sclerosis, 213
- Murray, Charles, 262
- music, 156; perception of, 142, 144; in synesthesia, 145–47, 152–53; talent for, 20, 50, 86, 97, 153
- mutation (process of), 38, 39, 40; and selection, 41–42, 43, 44, 170–71, 240
- mutations, 5, 10, 27, 38, 39, 40; and brain malformations, 64; de novo or new, 5, 27, 39, 40–42, 43, 44, 147, 157, 163, 169–71, 178, 181, 202, 222, 224, 227, 229–30, 233, 245–46, 250; and developmental robustness, 78–79, 235, 239; and eugenics, 252–53, 255–57, 259; high-risk, 224, 226, 232, 234, 238, 245; influence on traits, 48–49, 249–50, 251, 252; in model organisms, 64; and neurodevelopmental disorders, 217, 222–25, 226, 227–232, 233, 234–38, 240–42, 243, 244–46; and origins of sexual reproduction, 183–85; pathogenic, 225, 230, 235–36; point, 38, 40–42, 227; in the population, 41–45; and probabilistic neural development, 69–71, 73, 77; rare, 120–21, 179, 202, 224, 228, 232, 234–36, 245, 252; severe, 122, 162, 163, 177, 210, 224, 233, 236, 257. *See also* chromosomes, deletions or duplications of segments of; CNVs (copy number variants)
- mutation-selection balance, 43, 44, 240
- mutational load: and developmental robustness, 78–79, 235, 239; and eugenics, 256–57; and intelligence, 177, 177–79, 263
- mutational target, 240
- myelin, 21
- myopia, 135
- Nabokov, Vladimir, 146–47
- negative reinforcement, 117
- neglect, childhood, 29, 82–83, 85
- neonates, 190–98
- networks, brain or neuronal, 23, 25, 87, 89, 93, 116, 175; efficiency of, 176, 177; face-processing, 140, 141; sex differences in, 194, 196, 199
- neural circuits, 4, 50, 65, 80; in perception, 125, 133, 139; and personality, 103–104, 120; refinement of, 91; robustness of, 178; sex differences in, 185
- neural development: probabilistic nature of, 69–74; summary of processes of, 54–74
- neural fingerprint, 25
- neurexin-1. *See* *NRXN1*
- neuro-feedback, 247
- neurochemistry, 3; and personality, 104, 107; sex differences in, 187, 199; and synesthesia, 152
- neurodevelopmental disorders, 10, 65; clinical genetics of, 245–46; emergence of pathology in, 241, 244; and environmental factors, 219; genetic architecture of, 232, 233; genetic prediction of, 252–53; mutations causing, 226, 229–31; and personality traits, 123; sex differences in, 211, 213, 235. *See also* neurological disorders; psychiatric disorders
- neuroimaging. *See* imaging or neuroimaging
- neurological disorders, 199, 212, 217, 220
- neuromodulators: circuits, 113; and decision-making, 116; in development, 120; gating synaptic plasticity, 93, 94; and impulsivity, 116–18; and organization of behavior, 109, 111–12; variation in, 112, 114, 122, 124. *See also* acetylcholine; dopamine; noradrenaline; serotonin
- neurons, 57–61; excitatory, 59, 60, 61, 111; inhibitory, 59, 60, 61, 111; morphology of, 57, 58; types of, 57, 59, 242;
- neuropeptides, 109, 193
- neuroplasticity. *See* plasticity
- neurosexism, 214
- neuroticism, 100–102, 104, 109, 122, 158; and childhood trauma, 83; GWAS of, 106; and impulsivity, 114, 115; and self-help, 268–69; sex differences in 206
- neurotransmission, 58, 59, 110, 237; and synaptic plasticity, 87, 88
- neurotransmitter, 58, 59, 87, 110, 111, 117, 175, 252; receptors, 35, 58, 59, 87, 111
- Newell, Fiona, 147
- Newton, Isaac, 180
- noise, developmental, 15, 67–71, 74, 77–78; and genotype-phenotype relationships, 250; and intelligence, 177, 181–82; and neurodevelopmental disorders, 240; and neuromodulatory circuits, 114; and sexual differentiation, 203
- nongenetic effects or variation, 27–28; 70, 75; in intelligence, 179; in neurodevelopmental disorders, 244; in sexual orientation, 203

- nonshared environment. *See* environment, nonshared
- noradrenaline, 109, 116
- normal distribution. *See* distribution, normal
- novelty salience, 110, 115
- NRXN1*, 226, 237
- nucleus accumbens, 113
- nullisomy, 39
- number form, 144–45, 149
- nurturance, 206–207, 209
- nurture, 9–10, 12, 14, 84–86; and early brain plasticity, 81–82; and developmental variation, 51, 53–54; and intelligence, 165; nature of, 81–99; and personality traits, 103
- nurturing, 186
- nutrition, 26, 77, 166–67, 208, 263
- obesity, 27, 49
- obsessive compulsive disorder, 247
- odorant receptor, 134
- OFC. *See* cortex, orbitofrontal
- olfactory neurons, 134
- openness to experience or ideas, 83, 100–101; and educational attainment, 173; sex differences in, 206
- opsins, 117, 126, 128, 132, 135, 136, 136–37
- optic nerve, 87, 128
- optogenetics, 117–18
- ovaries, 188, 189
- oxytocin, 193
- pain, 49, 92, 135, 137, 193
- pair-bonding, 3, 193
- pallidum, 195
- parental behaviour or parenting, 2, 28–29, 53, 81, 83–84, 95, 95–96, 168, 264; in psychiatric disorders, 218, 222; sex differences in, 186, 193
- parietal lobe, 70, 175
- Parkinson's disease, 176, 247
- patterning, 55–57, 61, 64, 69
- peas, 31, 37
- peers, 52–53, 85, 95, 96, 198
- PER2*, 49
- perception, 14; as active inference, 126, 128–129, 130, 130–31; and critical periods, 90; differences in, 133–39; and formation of concepts, 139–154; and learning, 92; in neurodevelopmental disorders, 216, 242; relationship to gene function, 249; subjective, 125; and synesthesia, 143–154; and the *Umwelt*, 131–33
- personality traits, 1, 10, 13–15, 158; classification of, 100–103; and decision-making, 109, 110, 111–12; developmental influences on, 104, 122–24; and educational attainment, 173; environmental influences on, 53, 83; gene by environment effects on, 121–22; genes and circuits associated with, 105–107; and habits, 264; heritability of, 20, 104; and neuromodulators, 112, 114; in robots, 107–109; selection on, 259; and self-help, 266, 268–69; sex differences in, 187, 199, 205–209; sources of variance of, 103–104
- personality disorder, 121, 253
- PET (positron emission tomography), 151
- PFC. *See* cortex, prefrontal
- Phelan-McDermid syndrome, 237
- phenotypes, 15, 20, 48–49; prediction of, 252; probabilistic, 54, 70–71, 73, 74, 76–77, 222, 244; relationship to genotype, 27, 250, 252; sex differences in variance of, 208, 211; of synesthesia, 148–50
- phenylketonuria, 246
- phenylthiocarbamide, 134
- phoneme, 91, 149
- photoreceptor, 117, 126, 127, 135
- physiological states, 92, 111
- Pinker, Steven, 1, 28
- pioneer axons, 63, 71, 72
- PISA. *See* Programme for International Student Assessment
- plasticity: brain or synaptic, 59, 80–82, 86, 88, 89–91, 93, 94, 111, 118, 267, 269; and emergence of phenotypes, 198, 251; gating by neuromodulators, 111, 118, 119, 120, 174; in neurodevelopmental disorders, 237, 242, 243, 246; reduction with maturation, 99; sex differences in, 193, 199
- Plato, 1, 171
- play, rough-and-tumble, 204–205
- positive thinking, 266
- possession, demonic, 218
- post-traumatic stress disorder, 83
- predispositions, behavioral or innate, 13, 29, 81–82, 95; and determinism, 264–65; and self-help, 268
- primates, 156; sex differences in, 184, 186, 193, 198
- probabilistic relationship between genotypes and phenotypes, 70, 72, 73, 75, 77, 148, 202, 222, 252

- progesterone, 189
Programme for International Student Assessment (PISA), 212
proliferation, cellular, 64, 69, 174, 249
proprioception, 135
prosopagnosia. *See* face blindness
proteins: encoded by genes, 32–33, 34, 35–37; and epigenetics, 268; developmental variability in, 67–69; genetic variation affecting, 38, 39, 40–42, 49; regulation of expression of, 54–56; and what genes are for, 249
pruning, synaptic, 87, 89–90, 93, 148, 267
psilocybin, 152
psychiatric disorders, 20, 217–18; causes of, 218–20; clinical genetics of, 245–47; diagnostic categorisation of, 238–39; emergence of pathology in, 241–42, 243, 244; genetic architecture of, 222–24, 232, 233, 234–35; genetic origins of, 220–22; mutations causing, 224–25, 226, 227–30; persistence of, 239–41; sex differences in, 187, 212–13, 215, 235–36; types of genes implicated in, 236–38
psychoanalysis, 218
psychogenic theory of mental illness, 218, 222
psychological traits, 2, 7, 9, 11–13, 248–49, 251; comparing across people, 17, 20; and decision-making, 123–24; and determinism, 264; developmental effects on, 50–53, 73; group differences in, 258–60, 264; heritability of, 25, 45; measuring, 13; and maturation, 208; nongenetic effects on, 28–29, 82–86; and self-help, 269; sex differences in, 214
psychology, Freudian, 1
psychopath or psychopathy, 216, 253
psychosis, 49, 218, 223, 238, 241, 244, 266
psychotherapy, 217, 266
psychoticism (personality trait), 101
puberty, 189, 198, 200
punishment, 82, 110, 111, 115, 115, 117

quantum indeterminacy, 67
questionnaire, 13–15, 101, 115

race, 254, 258–64
Ramachandran, Vilayanur, 145
randomness in neural development, 8, 10, 50, 54, 67–68, 70, 73, 74, 74–76, 148, 154; and fluctuating asymmetries, 178; and genetic determinism, 264; and neurodevelopmental disorders, 233; and psychological traits, 73; and sexual differentiation, 203
raphe nuclei, 113
rats, 84, 115, 190, 204, 213
reaction time, 14, 159–60
reasoning, 100, 159, 212
receptivity, sexual, 189, 191
reductionism, 4, 15, 46, 265
Rees, Geraint, 138
Reeves, Keanu, 133
regression coefficient, 17
regulatory regions
relative risk, 231
replication. *See* DNA replication
reproduction, 43, 108, 183–84, 200, 250
resilience, 79, 83, 85, 122, 176, 178, 213, 240
resolution, perceptual, 128, 132–33; spatial, 135, 138, 154; temporal, 138
responsibility, moral, 266
retina, 57, 87, 89, 126, 127, 128–31, 135, 137–38
retinal axons or projections, 89, 127
retinal ganglion cells, 87, 126, 127, 128
Rett syndrome, 162, 223, 226
reward, 82, 92–94, 96–97, 111; and impulsivity, 114–17; sensitivity, 110, 110
ribonucleic acid. *See* RNA
ribosome, 35
Rich Harris, Judith, 28
risk aversion, 82, 93, 110, 110, 123; sex differences in, 206
risk taking, 101
RNA, 34, 35–37, 68
robots, 107–109
robustness, developmental, 76–78, 85, 240; and intelligence or IQ, 175–77, 177, 178–79; and neurodevelopmental disorders, 233, 235; sex differences in, 211, 236; variation in 78–79. *See also* buffering
Roche, Richard, 152
rods, 126, 127

Sacks, Oliver, 139
savant, 153, 181
savior sibling, 253
schema, 143, 149, 154
schizoaffective disorder, 239

- schizophrenia, 10, 75, 172, 216–18; and CNVs, 225, 226, 227; and emergent states, 241–42, 243, 244; familiarity and heritability of, 221–22; genes implicated in, 226, 236–38; genetic architecture of, 223–24, 232, 233, 234–35; genetic prediction of, 252, 257; GWAS of, 231; and intelligence or IQ, 179, 235; overlap in risk with other disorders, 238–39; and rare mutations, 225, 226, 227–30; and selection, 239–41; sex differences in, 212, 235–36
- Schopenhauer, Arthur, 179
- Schrödinger, Erwin, 32–33
- SCN1A, 246
- scoliosis, 135
- screening, genetic, prenatal, or pre-implantation, 79, 245, 247, 253, 256
- SDN-POA, 191, 195, 202
- seizure, 59, 70, 148, 218, 241, 246
- selection: artificial, 6, 259; balancing, 240; frequency-dependent, 260; genetic, 252–57; and intelligence, 157, 170–71, 173, 176–77, 207, 259, 263; natural, 6, 10, 41–42, 43, 44–45, 56, 250, 257, 260; negative, 171, 176, 239–40; and neurodevelopmental disorders, 239–40; positive, 41, 171; sexual, 185–87, 204; stabilizing, 263
- selective serotonin reuptake inhibitor (SSRI), 152
- self: sense of, 216; continuity of the, 266
- self-help, 266–69
- self-control, 114, 115, 266
- self-esteem, 101, 267, 269
- self-organizing processes of development, 10, 36, 71, 76, 81, 86–90, 124; and neurodevelopmental disorders, 242, 244
- sensation seeking, 101–102, 114, 115; sex differences in, 206
- sequence. *See* DNA sequence
- serotonin, 104, 109, 111–12; 113, 114; and aggression or impulsivity, 116–18, 119, 119–21; and synesthesia, 152
- serotonin receptors, 119, 119–121. *See also* *Htr1a*, *Htr1b*, *HTR2B*
- serotonin transporter (*5HTT*), 118, 119, 119, 121
- sex determination, 187, 189
- sexual differentiation, 183–85, 188–89, 193, 198, 201, 203
- sexual drive, 189
- sexual orientation, 20, 74, 200–203, 253
- sexual preference, 1, 185, 187, 200–203
- sexuality, 10, 183–215
- sexually dimorphic nucleus of the pre-optic area. *See* SDN-POA
- SHANK3*, 226, 237
- shared environment, *see* environment, family or shared
- Sibeliuss, Jean, 146
- siblings: adoptive, 13, 19–20, 28, 164, 222; biological, 16–17, 19–20, 164
- sickle-cell anemia, 38, 41, 49
- simian, 183
- single-nucleotide polymorphism (SNP) or variant (SNV), 44, 105, 173
- skin color, 258, 261
- Skinner, B.F., 145
- smoking, 20, 135; and lung cancer, 231
- SNP. *See* single-nucleotide polymorphism (SNP) or variant (SNV)
- SNV. *See* single-nucleotide polymorphism (SNP) or variant (SNV)
- sociability, 101, 123, 249–50; sex differences in 206
- sodium channel, 246
- speech, 91; disorders of, 216
- sperm, 13, 55, 184, 188; donors, 258; mutations arising in, 5, 27, 39, 45, 163, 171–72, 181, 222, 224, 227, 229
- spinal cord, 21, 57, 64
- SRY*, 188
- SSRI (selective serotonin reuptake inhibitor), 152
- stability, emotional. *See* emotional stability
- Stanford University, 159
- Stanford-Binet test, 159
- sterilization, 14, 254
- stochastic: developmental variation, 124, 143, 195; processes in development, 74
- stress: early life, 83–84, 96, 122; environmental, 122, 208; hormones, 193; maternal, 77, 79; in neurodevelopmental disorders, 222; and self-help, 267, 269
- striatum, 195, 242
- stroke, 176
- stupidity, genetics of, 170–72
- stuttering, 212
- substance abuse, 83. *See also* drug abuse
- substantia nigra, 113
- suicidality or suicide, 20, 83, 122, 171, 217, 257
- surgency, 102, 208
- Swaab, Dick, 202

- symmetry, facial and bodily, 66, 66; as general fitness indicator, 177, 178; sex differences in, 211; variation in 78–79
- synapse formation, 62, 64–65, 69–70, 120, 123, 174
- synapses, 58, 59, 70, 110–11, 117; modulation of, 93; refinement of, 86–87, 88, 99; in retina, 126; and serotonin, 118, 120; sex differences in, 192
- synaptic plasticity. *See* plasticity, synaptic
- synaptic pruning. *See* pruning, synaptic
- synesthesia, 143–46, 253; brain processes of, 151–54; emergence of, 148–50, 150; and savantism, 181
- syphilis, 223
- systemizing, 207
- tameness, 5, 7
- target selection, axonal or synaptic, 62, 63, 89, 128
- taste, 49, 133–35; receptors, 134; in synesthesia, 144–45
- temperament, 28, 102, 112, 124, 265; sex differences in, 208
- tendencies, innate, 2, 3, 5, 9, 252, 264; and personality traits, 109; reinforcement of, 94–96, 214; sex differences in, 190, 205, 207, 214
- Terman, Lewis, 159
- test-retest reliability, 15, 52, 102, 115; of IQ tests, 159–60, 165
- testes, 188, 189, 194, 229
- testosterone, 188, 189, 189–194, 202, 211, 236
- tetrachromatic (vision), 136, 137
- thalamus, 60, 87, 89, 93, 113, 127, 128–30, 192; sex differences in, 195
- threat sensitivity, 20, 82, 92–93, 108–109, 115, 123
- Thurman, Uma, 79
- thymine, 33
- Timothy syndrome, 223
- tone deafness. *See* tune deafness
- tool making, 156
- topography, 89
- touch, 89, 132, 135, 144
- Tourette's syndrome, 212
- Tph2*. *See* tryptophan hydroxylase
- trade, 156
- transcription, 35, 68
- transcription factor, 188
- translation, 36
- trauma, 83, 85
- trichromatic (vision), 136, 136–37
- Trinity College Dublin, 32
- trisomy, 39. *See also* Down syndrome
- tryptophan, 118, 119
- tryptophan hydroxylase, 119, 119, 120
- tuberous sclerosis, 223
- tune deafness, 142
- twin studies, 9, 12–14, 16, 16–20, 27, 45, 51, 84, 249; of autism, 221, 234; of brain function, 24–25; of brain structure, 20–21, 22, 23, 65; of epilepsy, 70, 75, 148; of face recognition, 142; and family environment, 84–86; of intelligence, 97, 164–66, 168, 180, 262; of life experiences, 96; and nongenetic effects, 28–30, 51–53, 65; of personality, 103–104; of schizophrenia, 221–22, 234; of sexual orientation, 201, 203
- twins, identical or monozygotic, variation between, 52–53, 65, 70, 73–75, 78, 179, 181
- Umwelt*, the, 131–33
- uncertainty, in decision-making, 111
- United Kingdom: eugenics in, 14, 255; IQ in, 167
- United States: eugenics in, 14, 254–55, 257; racial inequities in, 167, 263
- upbringing, 2, 17, 74, 84–86; and intelligence, 164, 179; and neurodevelopmental disorders, 221; and personality, 103
- utility, in decision-making, 111, 116
- V1 (cortical area), 127
- V2 (cortical area), 127
- V3 (cortical area), 127
- V3a (cortical area), 127
- V4 (cortical area), 127, 151
- V8 (cortical area), 151
- vaccine, 218–20
- value, affective or subjective, 92–94, 108, 111
- variance, 18, 19, 19, 25, 48; genetic contribution to (heritability), 25–27, 45; from family environment, 84–86, 96; nongenetic sources of, 28–30, 203, 244; third component of, 51–52, 54, 74
- variants, common, 56, 104–105, 105, 106; and intelligence or IQ, 172–74; and neurodevelopmental disorders, 231–32, 234–36;

- and personality traits, 121. *See also* single-nucleotide polymorphism or variant variants, rare, 45; and intelligence or IQ, 172–73, 177; and personality traits, 123. *See also* mutations
- vasopressin, 193
- velo-cardio-facial syndrome, 223, 225
- ventral tegmental area, 113
- verbal fluency, 159
- violence: and personality, 121; sex differences in, 186, 204–205, 214
- visual cortex. *See* cortex, visual
- visual-spatial processing, 159
- vitamin D, 259
- vocabulary: color terms, 137; and IQ, 159–60
- von Neumann, John, 180–81
- von Uexküll, Jakob, 131
- Waddington, Conrad, 74, 76–77
- Wade, Nicholas, 261
- Wakefield, Andrew, 219–20
- Ward, Jamie, 153
- warmth, 20, 100; sex differences in, 206
- West, Kanye, 146
- white matter, 21, 23, 60; and IQ, 175; sex differences in, 198; and synesthesia, 152
- Williams, Pharell, 146
- Williams syndrome, 162
- wolves, 5, 6
- working memory, 159
- X chromosome, 187–89, 189, 192–93; and fragile X syndrome, 223; inactivation, 193; and MAOA gene, 120; and neurodevelopmental disorders, 235–36; and opsin genes, 135, 136, 136–37; and X-linked disorders, 163, 211
- Y chromosome, 163, 187–89, 189, 193, 200, 202; and neurodevelopmental disorders, 236
- zygote, 13